Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2014, Vol. 36 ›› Issue (3): 305-308.doi: 10.3881/j.issn.1000-503X.2014.03.014

• Original Articles • Previous Articles     Next Articles

Comparison of Efficacy and Safety between Liposome-paclitaxel Injection plus Carboplatin and Paclitaxel plus Carboplatin as First Line Treatment in Advanced Non-small Cell Lung Cancer

WANG Hong-yu,ZHANG Xiang-ru   

  1. Department of Medical Oncology,Cancer Institute & Hospital,CAMS and PUMC,Beijing 100021,China
  • Received:2013-12-11 Online:2014-06-28 Published:2014-06-28
  • Contact: WANG Hong-yu Tel:010-87788159,Fax:010-87788113,


Objective To compare the efficacy and safety between liposome-paclitaxel plus carboplatin(LPC)and paclitaxel plus carboplatin(PC)as first-line treatment for advanced non-small cell lung cancer(NSCLC). Methods Totally 54 chemotherapy-nave NSCLC patients were equally and randomly assigned into LPC group and PC group. Liposome-paclitaxel was injected on D1 at a dosage of 175 mg/m2;the same dose and administration with paclitaxel injection in the PC group for a maximum of 2 cycles. The efficacy and adverse reactions after 2 cycles of chemotherapy were compared between these two groups. Results The overall response rate(CR+PR)was 44.4% in the LPC group and 33.3% in the PC group after 2 cycles of chemotherapy respectively(P=0.577). In the LPC group and PC group,the incidences of myelodepression was 81.5% and 63.0%,respectively(P=0.080),gastrointestinal toxicity was 96.3% and 77.8% respectively(P=0.100),and allergic reactions was 0 and 11.1%,respectively(P=0.000).The median time to progression was 6 months and 5 months,respectively(P=0.420). Conclusion LPC group has the same efficacy with PC group and less adverse reactions than PC group.

Key words: liposome-paclitaxel injection, paclitaxel injection, non-small cell lung cancer, chemotherapy, efficacy, safety

CLC Number: